PriceTargets.com logo

Immuron - IMRN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 133.10%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.15 As of 01/17/2025 04:59 PM ET
▲ +0.145 (7.25%)
Get New Immuron Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMRN

Analyst Price Target is $5.00
▲ +133.10% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Immuron in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 133.10% upside from the last price of $2.15.

This chart shows the closing price for IMRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Immuron.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/16/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/26/2024Litchfield Hills ResearchInitiated CoverageBuy$5.00
(Data available from 1/17/2020 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
1/17/2025

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Immuron logo
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.
Read More

Today's Range

Now: $2.15
Low: $1.85
High: $2.13

50 Day Range

MA: $5.04
Low: $4.80
High: $5.61

52 Week Range

Now: $2.15
Low: $1.92
High: $28.99

Volume

12,391 shs

Average Volume

10,070 shs

Market Capitalization

$12.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Immuron?

The following Wall Street analysts have issued reports on Immuron in the last twelve months: Litchfield Hills Research.
View the latest analyst ratings for IMRN.

What is the current price target for Immuron?

0 Wall Street analysts have set twelve-month price targets for Immuron in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 128.7%. Litchfield Hills Research has the highest price target set, predicting IMRN will reach $5.00 in the next twelve months. Litchfield Hills Research has the lowest price target set, forecasting a price of $5.00 for Immuron in the next year.
View the latest price targets for IMRN.

What is the current consensus analyst rating for Immuron?

Immuron currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMRN will outperform the market and that investors should add to their positions of Immuron.
View the latest ratings for IMRN.

What other companies compete with Immuron?

Other companies that are similar to Immuron include Grace Therapeutics, vTv Therapeutics, Clene, RAPT Therapeutics and Barinthus Biotherapeutics. Learn More about companies similar to Immuron.

How do I contact Immuron's investor relations team?

Immuron's physical mailing address is 62 LYGON STREET LEVEL 3, CARLTON C3, 3053. The company's listed phone number is (138) 892-4854 and its investor relations email address is [email protected]. The official website for Immuron is www.immuron.com.au. Learn More about contacing Immuron investor relations.